D
AbCellera Biologics Inc.
ABCL
$2.39
$0.052.14%
D
Sell
1/22/2025Upgraded
AbCellera Biologics Inc. (ABCL) was upgraded to D- from E+ on 1/22/2025 due to an increase in the total return index, volatility index and valuation index.
AbCellera Biologics Inc. (ABCL) was upgraded to D- from E+ on 1/22/2025 due to an increase in the total return index, volatility index and valuation index.
E
Sell
5/22/2024Downgrade
AbCellera Biologics Inc. (ABCL) was downgraded to E+ from D on 5/22/2024 due to a significant decline in the efficiency index, solvency index and growth index. Operating cash flow declined 112.68% from -$19.61M to -$41.71M, and total capital declined 2.13% from $1.23B to $1.2B.
AbCellera Biologics Inc. (ABCL) was downgraded to E+ from D on 5/22/2024 due to a significant decline in the efficiency index, solvency index and growth index. Operating cash flow declined 112.68% from -$19.61M to -$41.71M, and total capital declined 2.13% from $1.23B to $1.2B.
D
Sell
5/8/2023Downgrade
AbCellera Biologics Inc. (ABCL) was downgraded to D from D+ on 5/8/2023 due to a significant decline in the valuation index, efficiency index and growth index. Operating cash flow declined 242.54% from $30.91M to -$44.06M, EBIT declined 71.72% from -$37.78M to -$64.87M, and total revenue declined 43.41% from $21.55M to $12.19M.
AbCellera Biologics Inc. (ABCL) was downgraded to D from D+ on 5/8/2023 due to a significant decline in the valuation index, efficiency index and growth index. Operating cash flow declined 242.54% from $30.91M to -$44.06M, EBIT declined 71.72% from -$37.78M to -$64.87M, and total revenue declined 43.41% from $21.55M to $12.19M.
D
Sell
10/17/2022Upgraded
AbCellera Biologics Inc. (ABCL) was upgraded to D+ from D on 10/17/2022 due to an increase in the volatility index and total return index.
AbCellera Biologics Inc. (ABCL) was upgraded to D+ from D on 10/17/2022 due to an increase in the volatility index and total return index.
D
Sell
9/30/2022Downgrade
AbCellera Biologics Inc. (ABCL) was downgraded to D from D+ on 9/30/2022 due to a decline in the total return index.
AbCellera Biologics Inc. (ABCL) was downgraded to D from D+ on 9/30/2022 due to a decline in the total return index.
D
Sell
8/31/2022Upgraded
AbCellera Biologics Inc. (ABCL) was upgraded to D+ from D on 8/31/2022 due to an increase in the valuation index, total return index and volatility index.
AbCellera Biologics Inc. (ABCL) was upgraded to D+ from D on 8/31/2022 due to an increase in the valuation index, total return index and volatility index.
D
Sell
8/16/2022Downgrade
AbCellera Biologics Inc. (ABCL) was downgraded to D from D+ on 8/16/2022 due to a significant decline in the growth index, solvency index and volatility index. Earnings per share declined from $0.54 to -$0.0238, EBIT declined 103.73% from $224.95M to -$8.4M, and total revenue declined 85.5% from $316.58M to $45.92M.
AbCellera Biologics Inc. (ABCL) was downgraded to D from D+ on 8/16/2022 due to a significant decline in the growth index, solvency index and volatility index. Earnings per share declined from $0.54 to -$0.0238, EBIT declined 103.73% from $224.95M to -$8.4M, and total revenue declined 85.5% from $316.58M to $45.92M.
D
Sell
8/12/2022Upgraded
AbCellera Biologics Inc. (ABCL) was upgraded to D+ from D on 8/12/2022 due to a significant increase in the valuation index, efficiency index and volatility index. Net income increased 181.2% from $59.95M to $168.57M, and total capital increased 17.07% from $1.07B to $1.25B.
AbCellera Biologics Inc. (ABCL) was upgraded to D+ from D on 8/12/2022 due to a significant increase in the valuation index, efficiency index and volatility index. Net income increased 181.2% from $59.95M to $168.57M, and total capital increased 17.07% from $1.07B to $1.25B.
D
Sell
4/20/2021Downgrade
AbCellera Biologics Inc. (ABCL) was downgraded to D from D+ on 4/20/2021 due to a decline in the total return index, volatility index and valuation index.
AbCellera Biologics Inc. (ABCL) was downgraded to D from D+ on 4/20/2021 due to a decline in the total return index, volatility index and valuation index.
D
Sell
4/5/2021Upgraded
AbCellera Biologics Inc. (ABCL) was upgraded to D+ from D- on 4/5/2021 due to a significant increase in the growth index, efficiency index and valuation index. EBIT increased 9,303.12% from -$1.77M to $162.67M, net income increased 4,446.84% from -$2.69M to $117M, and earnings per share increased from -$0.0134 to $0.3448.
AbCellera Biologics Inc. (ABCL) was upgraded to D+ from D- on 4/5/2021 due to a significant increase in the growth index, efficiency index and valuation index. EBIT increased 9,303.12% from -$1.77M to $162.67M, net income increased 4,446.84% from -$2.69M to $117M, and earnings per share increased from -$0.0134 to $0.3448.
D
Sell
3/26/2021Downgrade
AbCellera Biologics Inc. (ABCL) was downgraded to D- from D on 3/26/2021 due to a decline in the total return index and volatility index.
AbCellera Biologics Inc. (ABCL) was downgraded to D- from D on 3/26/2021 due to a decline in the total return index and volatility index.
D
Sell
3/11/2021Upgraded
AbCellera Biologics Inc. (ABCL) was upgraded to D from D- on 3/11/2021 due to an increase in the total return index and volatility index.
AbCellera Biologics Inc. (ABCL) was upgraded to D from D- on 3/11/2021 due to an increase in the total return index and volatility index.
D
Sell
3/10/2021None
AbCellera Biologics Inc. (ABCL) was downgraded to D- from U on 03/10/2021.
AbCellera Biologics Inc. (ABCL) was downgraded to D- from U on 03/10/2021.
NASDAQ
03/05/2025 4:00PM Eastern
Quotes delayed
